UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~March~~May 3116, 2011

TIENS BIOTECH GROUP (USA), INC.

(Exact name of registrant as specified in its charter)


Delaware	001-32477	75-2926439
(State or other jurisdiction	(Commission File Number)	(I.R.S. Employer
of incorporation)		Identification Number)

No. 17, Xinyuan Rd., Wuqing New Tech Industrial Park, Tianjin, China ~~301700~~30170

(Address of principal executive offices)

Registrant’s telephone number, including area code: (~~011)~~ 86)-22-8213-7914

~~_______________________________________________________~~No. 6, Yuanquan Rd., Wuqing New Tech Industrial Park, Tianjin, China 301700

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting materials pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Soliciting materials pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On ~~March~~May 3116, 2011, Tiens Biotech Group (USA), Inc. (the “Company”) issued a press release ~~announcing~~reporting ~~its~~the Company’s financial results for the fiscal ~~year~~quarter ended ~~December~~March, 31, ~~2010~~2011. The full text of the press release is set forth in Exhibit 99.1 attached hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

~~Exhibit Number~~	~~Description~~Exhibit Number	Description
~~99.1~~	~~Press Release, dated March 31, 2011~~99.1	Press release, dated May 16, 2011.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TIENS BIOTECH GROUP (USA), INC.
Date: March 31, 2011	By: /s/ Jinyuan Li
Date: May 16, 2011	By:	/s/ Jinyuan Li
	~~Name: Jinyuan Li~~	Name: Jinyuan Li
	~~Title: Chief Executive Officer~~	Title: Chief Executive Officer

Exhibits

~~Exhibit Number~~	~~Description~~Exhibit Number	Description
~~99.1~~	~~Press Release, dated March 31, 2011~~99.1	Press release, dated May 16, 2011.

Filing Compare · TIENS BIOTECH GROUP USA INC